Trius Therapeutics, Inc.
TSRX today announced that the underwriters of its previously
announced public offering of common stock that priced on January 17, 2013,
have exercised their option to purchase an additional 869,135 shares of common
stock. With the sale of the additional shares, Trius will have sold a total of
7,169,135 shares of common stock in the public offering at a price to the
public of $4.75 per share, resulting in expected aggregate gross proceeds to
Trius of approximately $34.1 million, before deducting underwriting discounts
and commissions and other estimated offering expenses payable by Trius. The
offering, including the sale of the additional shares, is expected to close on
or about January 24, 2013, subject to customary closing conditions.
Trius anticipates using the net proceeds from the offering for general
corporate purposes, including clinical trial, preclinical and other research
and development expenses, capital expenditures, working capital and general
and administrative expenses.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in